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using opioids, 44% used short-acting, 19% long-acting, and 37% both. Prevalence of
OpA among those with a history of opioid use was 0.56% compared to 0.06% in
non-users (p0.0001). All HCRU was significantly greater for the pre-index and
post-index periods for OpAers compared to controls (p0.0001). Total health care
costs were greater for OpAers compared with controls; $11,13726,677 versus
$2,2318,438 (p0.0001) in the pre-index and $25,65454,928 vs. $4,90218,682
(p0.0001) in the post-index periods, respectively. Prescription opioid costs for
OpAers and controls was $1,9356844 and $34486 (p0.0001), respectively.
Among OpAers, total healthcare costs were greater for those with pre-index opioid
use compared with those without pre-index opioid use; $13,92030,012 versus
$5,22216,073 (p0.0001) in the pre-index and $29,50056,713 versus
$17,48149,960 (p0.0001) in the post-index periods. CONCLUSIONS: OpAers have
significantly greater HCRU and total cost before and after OpA compared to
matched controls. OpAerswith opioid use had significantly greater total cost before
and after OpA than OpAers without opioid use.
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OBJECTIVES: To identify the incidence and prevalence of idiopathic inflammatory
myopathies (IIMs) among commercially insured and Medicare and Medicaid en-
rolled populations in theUS, using administrative claims data. IIMs are a rare group
of autoimmune syndromes characterized by chronic muscle inflammation and
muscle weakness with no known cause. Little is known about their incidence and
prevalence.METHODS:Medical claims with an IIM diagnosis (ICD-9-CM 710.3 [der-
matomyositis (DM)], 710.4 [polymyositis (PM)], 728.81[interstitial myositis]) were
retrospectively examined in the MarketScan® databases to identify age- and gen-
der-adjusted annual IIM incidence and prevalence for 2004-2008. Sensitivity anal-
ysis was performed for evidence of a specialist visit (rheumatologist/ neurologist/
dermatologist), systemic corticosteroid or immunosuppressant use, or muscle
biopsy. RESULTS: A total of 2990 incident patients between 2004 and 2008 (67%
female, 17% Medicaid enrollees, 27% aged 65 years) were identified. Overall ad-
justed IIM incidence for 2004-2008 for commercial and Medicare supplemental
groups combined were 4.27 cases (95% CI, 4.09-4.44) and for Medicaid, 5.23 (95% CI
4.74-5.72) per 100,000 person-years (py). Disease sub-type incidence rates per
100,000-py were 1.52 (95% CI 1.42-1.63) and 1.70 (1.42-1.97) for DM, 2.46 (2.33-2.59)
and 3.53 (3.13-3.94) for PM, and 0.73 (0.66-0.81) and 0.78 (0.58-0.97) for interstitial
myositis for the commercial/Medicare and Medicaid cohorts respectively. Annual
incidence fluctuated over time with the base MarketScan populations. There were
7,155 prevalent patients, with annual prevalence ranging from 20.62 to 25.32 per
100,000 for commercial/Medicare (83% of prevalent cases) and from 15.35 to 32.74
for Medicaid. Sensitivity analysis reduced the incidence rates and prevalence by
20-40%. CONCLUSIONS: This study found higher IIM incidence and prevalence
than historical small population based reports. Employer turnover, miscoding and
misdiagnosing, care seeking behavior, and fluctuations in database membership
over time can influence the results. Further studies are needed to confirm the
incidence and prevalence of IIMs in the US population.
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OBJECTIVES: Modifiable risk factors in the US workforce have been documented
previously, but knowledge of behavioral risk factor prevalence among working
adults remains incomplete. Toassess currentnational estimates for smoking,heavier
alcohol consumption, obesity, insufficient exercise and fair/poor health status for
working adults aged 20 years and older.METHODS: Analysis of nationally represen-
tative data collected from employed adults 20 years and older participating in the
National Health Interview Survey (NHIS) 2010 (aged 20 to 64 years, n 13,844, aged
20 to 39 years, n6,495, aged 40 to 64 years, n7,349, men aged 20 to 64 years 
6,825, women aged 20 to 64 years  7,019). RESULTS: The prevalence of current
smoking amongworking adults aged 20 to 64 years is 19.6%; younger workers (aged
20 to 39 years) have a significantly higher prevalence of current smoking than
workers 40 to 64 years, (21.2% vs. 18.3%, p0.001) and employed men have a sig-
nificantly higher smoking prevalence than employed women (21.4% vs. 17.6%, re-
spectively, p0.0001). An estimated 5.7% and 5.5% of working men and women,
respectively, report heavier alcohol consumption (p0.5573, 2 drinks/day for men,
1 drink/day forwomen). The prevalence of insufficient exercise is equivalent among
working men and women, 30.6% and 31.0%, respectively. Obesity prevalence in the
workforce is 33.5%; obesity rates are 31.6% and 35.1% among workers 20 to 39 years
and 40 to 64 years, respectively (p0.2665). Employed women and men are equally
likely to report that their health is fair/poor (6.0% vs. 5.1%). CONCLUSIONS: Current
smoking, insufficient exercise and obesity are prevalent in the US workforce. Ef-
fective workplace approaches including increased dissemination of educational
information are needed to reduce the burden of these risk factors.
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OBJECTIVES: Tapentadol ER is a new oral analgesic that has been shown to have a
lower incidence of gastrointestinal adverse events (AEs) than oxycodone CR at
equianalgesic doses.We estimated the annual budget impact of placing tapentadol
ER on a health plan formulary of long-acting opioids (LAOs) used to treat moderate
to severe chronic pain. METHODS: An Excel-based budget impact model was de-
veloped to estimate the annual direct healthcare costs associated with long-acting
formulations of tapentadol, oxycodone, morphine, hydromorphone, oxymor-
phone, and fentanyl. Costs included medications, copayments, AE management
and opioid switching/discontinuation. Incidence/prevalence estimates, AEs and
pain management resources and costs (medications, physician phone calls, office
visits, emergency room visits and hospitalizations) were based on published
sources. Drug costswere based onwholesale acquisition cost. All costswere in 2010
US dollars. Weighted-average daily drug consumption (DACON) and formulary
sharewere obtained from IMSHealth. Base case analysis assumed a 10% formulary
share of tapentadol ERwith a 10% decrease of oxycodone CR. Results are presented
as the per-member per-month (PMPM) cost difference after adding tapentadol ER to
the formulary. RESULTS: In a health plan of 500,000 members, 2,600 (0.52%) would
be expected to experience chronic pain annually and be treated with an LAO for an
average of 180 days. Adding tapentadol ER to the formulary (10% share) decreased
both pharmacy (-$0.0136 PMPM) andmedical (-$0.0008 PMPM) costs as well as total
costs (-$0.0144 PMPM), with annual budget savings of $85,992. This was driven by
lower DACON and lower incidence of AEswith tapentadol ER versus oxycodone CR,
leading to reduced resource use and costs. In sensitivity analysis, resultsweremost
sensitive to drug acquisition costs. CONCLUSIONS: Results suggest that increasing
market share of tapentadol ER while reducing oxycodone CR would decrease a
health plan’s budget by decreasing both pharmacy and medical costs.
PSY13
EFFECT OF RISK-SHARE AGREEMENTS ON BUDGET IMPACT: A CASE STUDY OF
CERTOLIZUMAB PEGOL IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Fust K1, Parthan A1, O’Sullivan AK1, Bedenbaugh A2
1OptumInsight, Medford, MA, USA, 2UCB, Smyrna, GA, USA
OBJECTIVES: Illustrate potential budgetary impact of a risk-share agreement in a
US health plan using a case study of certolizumab pegol (CZP) as treatment for
moderate to severe rheumatoid arthritis (RA).METHODS: An economic model was
developed to evaluate the budget impact to a hypothetical 50 million member
health plan of adding CZP to a formulary. The target population was patients naïve
to TNF inhibitors. Model comparators included adalimumab, etanercept, inflix-
imab, and golimumab. Comparable efficacy is assumed across therapies; discon-
tinuation rates were assumed to differ by therapy, as evidenced by claims data.
Model parameters were estimated using published data, market research, and an
administrative claims database analysis. The base-case included a risk-share com-
ponent for which the health plan received a rebate for clinically non-responsive
CZP patients at week 12. Non-responsive CZP patients were assumed to receive an
alternative TNF-alpha inhibitor for the remainder of the 3-year model horizon.
Analyses captured differences in drug acquisition and intravenous administration
costs for the base-case and an alternate scenario assuming no risk-share agree-
ment. Deterministic sensitivity analyseswere also conducted.RESULTS:Assuming
a risk-share agreement, per-patient per-month (PPPM) savings in years 1, 2, and 3
were $4.22, $2.26, and $2.26, respectively. Applied to a hypothetical health-plan of
50 million members, annual cost savings are $3.6M, $2M, and $2.1M in years 1, 2,
and 3, respectively. Without a risk-share agreement, PPPM savings were $3.27 in
year 1 and $2.21 in years 2 and 3. Model results were most sensitive to average
monthly pharmacy costs of CZP and infliximab. CONCLUSIONS: The analysis sug-
gests that under a risk-share agreement, the addition of CZP to a US health plan
formulary may result in cost savings to the plan. Additionally, even without a
risk-share agreement, the addition of CZP may provide cost savings.
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OBJECTIVES: This study aimed to compare direct healthcare costs and opioid use
over a 1-year period following initiation with duloxetine versus other standard of
care (SOC) treatments among patients with chronic low back pain (CLBP).
METHODS: This retrospective cohort study assessed commercially-insured Mar-
ketscan CLBP patients aged 18-64 years who initiated duloxetine or other treat-
ments (tricyclic antidepressants, venlafaxine, pregabalin, gabapentin, muscle re-
laxants and opioids) in 2009. The first dispense date was defined as the index date.
Selected patientswere required to have at least two lowback pain (LBP) inpatient or
outpatient claims with at least 90 days gap between the 2 in the 12-month pre-
index period. Both duloxetine and SOC cohorts were then matched via propensity
scoring (n668 for each cohort), controlling for demographics, comorbidities, prior
healthcare utilization and costs, and prior medication history. Health care costs
and opioid use (among patients not initiated on opioids) over the 12-month post-
index period were compared between cohorts. RESULTS: Total health care costs
over the 12-month post-index period were $17,435 among duloxetine-initiated pa-
tients, versus $19,633 (p0.1781) for SOC-initiated patients. Duloxetine-initiated
patients also had significantly lower inpatient costs ($3,486 vs. $5,975, p0.0219).
While both groups had similar outpatient costs ($9,558 vs. $10,424, p0.3324),
CLBP-related outpatient costs were significantly lower among duloxetine-initiated
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